1
artículo
Publicado 2020
Enlace
Enlace
Adult T - lymphoma / leukemia is an aggressive T lymphoproliferative entity associated retrovirus HTLV-1- T.HTLV-1 infection is endemic in Japan, the Caribbean, Africa, South America, and the Middle East. In South America, we have Peru, Brazil, Colombia and Chile.Peru is endemic for this virus. The prevalence of retroviruses in Europe and the USA. USA It is less than 1% but in Peru it is estimated that around 3% of the healthy adult population is a carrier of the retrovirus.From Chile, there have been several ATLL reports since 1992 by Dra. Cabrera et al.
2
artículo
Adult T - lymphoma / leukemia is an aggressive T lymphoproliferative entity associated retrovirus HTLV-1- T.HTLV-1 infection is endemic in Japan, the Caribbean, Africa, South America, and the Middle East. In South America, we have Peru, Brazil, Colombia and Chile.Peru is endemic for this virus. The prevalence of retroviruses in Europe and the USA. USA It is less than 1% but in Peru it is estimated that around 3% of the healthy adult population is a carrier of the retrovirus.From Chile, there have been several ATLL reports since 1992 by Dra. Cabrera et al.
3
artículo
Publicado 2018
Enlace
Enlace
En presente artículo hace un análisis de la relación relación neutrófilos-linfocitos en pacientes con linfoma periférico de células T agresivo en estadio temprano, donce se incluyeron pacientes con diagnóstico de PTCL.
4
artículo
Publicado 2009
Enlace
Enlace
El desarrollo de linfomas de células B ha sido descrito raramente en portadores del virus linfotrópico humano de células T de tipo 1 (HTLV-1). Se presenta el caso de un portador de HTLV-1 peruano de edad avanzada que fue diagnosticado con el virus Epstein Barr (EBV) - Linfoma de células B grandes difuso. A pesar de una buena respuesta inicial a la terapia el paciente murió durante el tratamiento debido a neumonía fatal por Pneumocystis jiroveci. En este paciente la combinación de coinfección de EBV y HTLV-1 y la inmunosenescencia puede haber jugado un rol en el desarrollo de un agresivo Linfoma de células B grandes difuso. Además, la inmunodeficiencia causada por la quimioterapia y la infección viral puede haber facilitado el desarrollo de complicaciones infecciosas con amenaza de vida.
5
artículo
Publicado 2019
Enlace
Enlace
Peripheral T cell lymphoma (PTCL) is rare in the United States and Europe, accounting for about 10% of all lymphoma cases. In Latin America, PTCL accounts for about 15–20% of all lymphoma cases (Laurini et al, 2012). Aggressive subtypes of PTCL carry a poor prognosis with a 5‐year overall survival (OS) of approximately 30%, and include unspecified (PTCLU), anaplastic large cell lymphoma (ALCL) and angioimmunoblastic lymphoma, among others (Vose et al, 2008). The International Prognostic Index (IPI) and the Prognostic Index for PTCLU (PIT) scoring systems are powerful risk‐stratification tools that have been validated in patients with aggressive PTCL. The prognosis of aggressive PTCL patients is, however, heterogeneous and further refinement of prognostic tools is needed. The neutrophil‐lymphocyte ratio (NLR) has been shown to be prognostic in patients with a variety of haematolog...
6
artículo
Publicado 2025
Enlace
Enlace
Introduction: Diffuse large B cell lymphoma is the most common subtype of lymphoma. Albumin proves to be a prognostic factor in this subtype of lymphoma. Objective: The objective of this study is to evaluate the role of albumin in the survival of elderly patients with diffuse large B cell lymphoma in a hospital in Peru. Material and methods: This was a retrospective study of 62 patients with diffuse large B cell lymphoma aged 80 or older. Results: In the multivariate analysis, bulky disease (HR= 3.1, 95% 1.5-6.4; p=0.003) and albumin (HR 3.8, 95% 1.9-7.6; p=0.001) were factors associated with survival. Conclusions: bulky disease and albumin were factors associated with overall survival in patients with diffuse large B cell lymphoma aged 80 or older.
7
artículo
Publicado 2021
Enlace
Enlace
Se ha descrito embolización sistémica hasta en un 40% de los pacientes con mixoma auricular izquierdo, la mitad de ellos con afectación cerebral. Sin embargo, el desarrollo de embolización intracerebral asociada con la siembra parenquimatosa de los émbolos de mixoma es una complicación extremadamente rara, con solo 36 casos diagnosticados histológicamente reportados en la literatura publicada. Se describe a una mujer de 69 años que acude al servicio de urgencias por hemiparesia asociada a epilepsia farmacorresistente y antecedente de resección de mixoma auricular izquierdo 10 meses antes. La tomografía computarizada de cráneo reveló múltiples lesiones grandes de densidad heterogénea y componentes quísticos en los lóbulos occipitales y el parénquima de la fosa posterior. El análisis histopatológico tras biopsia estereotáxica de la lesión occipital reveló células de ...
8
artículo
Publicado 2018
Enlace
Enlace
El linfoma difuso de células B grandes (LDCBG) positivo al VEB, no especificado de otra manera (NOS) es un subtipo de linfoma agresivo poco común asociado con un peor pronóstico en los ancianos. Se ha informado DLBCL positivo para EBV en <5% de los pacientes occidentales sin inmunodeficiencia predisponente documentada. Existen muchos trastornos linfoproliferativos asociados con la infección por VEB, como granulomatosis linfomatoide, linfoma plasmablástico, LDCBG asociado con inflamación crónica, úlcera mucocutánea positiva para VEB, linfoma de derrame primario y linfoma de Hodgkin clásico. El LDCBG EBV-positivo, NOS es un diagnóstico de exclusión y se requiere una correlación clínico-patológica para diferenciar entre estos diagnósticos diferenciales. Los pacientes con enfermedad inflamatoria intestinal (EII) que reciben medicamentos inmunosupresores tienen un mayor riesgo...
9
artículo
Publicado 2018
Enlace
Enlace
Disease overview Epstein Barr virus‐positive (EBV+) diffuse large B‐cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the 2016 WHO classification of lymphoid neoplasms. EBV+ DLBCL, NOS, is an aggressive B‐cell lymphoma associated with chronic EBV infection, and a poor prognosis with standard chemotherapeutic approaches. Diagnosis The diagnosis is made through a careful pathological evaluation. Detection of EBV‐encoded RNA is considered standard for diagnosis; however, a clear cutoff for positivity has not been defined. The differential diagnosis includes plasmablastic lymphoma, DLBCL associated with chronic inflammation, primary effusion lymphoma, HHV8+ DLBCL, NOS, and EBV+ mucocutaneuos ulcer. Risk‐stratification The International prognostic index (IPI) and the Oyama score can be used for risk‐stratification. The Oyama score includes age >70 years...
10
artículo
Publicado 2020
Enlace
Enlace
The disease by the new coronavirus strain (COVID-19) has been classified as apandemic by the WHO. In Peru, a state of national emergency and compulsory socialisolation had been declared since 15 March. Global health systems have been greatlyimpacted by COVID-19, which forced health systems, societies and medicalassociations to design prioritized intervention strategies to provide continuity of patientcare in infected areas and COVID-19-free areas. A cancer patient is classified asvulnerable and represents a risk factor for complications due to COVID-19, such asadmission to the intensive care unit, intubation, and early death due to infection due toCOVID-19. This is how the Asociación de Médicos Ex Residentes de OncologíaMédica (AMEROM), has endeavored to give recommendations adaptable to our healthsystem, to continue with the prioritized care of cancer patients. Through the modifiedm...
11
artículo
Publicado 2020
Enlace
Enlace
The disease by the new coronavirus strain (COVID-19) has been classified as apandemic by the WHO. In Peru, a state of national emergency and compulsory socialisolation had been declared since 15 March. Global health systems have been greatlyimpacted by COVID-19, which forced health systems, societies and medicalassociations to design prioritized intervention strategies to provide continuity of patientcare in infected areas and COVID-19-free areas. A cancer patient is classified asvulnerable and represents a risk factor for complications due to COVID-19, such asadmission to the intensive care unit, intubation, and early death due to infection due toCOVID-19. This is how the Asociación de Médicos Ex Residentes de OncologíaMédica (AMEROM), has endeavored to give recommendations adaptable to our healthsystem, to continue with the prioritized care of cancer patients. Through the modifiedm...
12
artículo
Publicado 2023
Enlace
Enlace
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive mature T-cell neoplasm caused by infection with the Human T-cell Lymphotropic Virus Type 1 (HTLV-1). Cardiac involvement in patients with ATLL is infrequent, and when it happens it is usually seen in aggressive ATLL subtypes. However, ATLL presenting as isolated cardiac valve involvement is extremely rare. To date, only three histologically proven cases of ATLL with isolated cardiac valve involvement have been reported. Herein, we describe a 61-year-old Peruvian man who presented heart failure symptoms secondary to progressive cardiac valve infiltration. The patient underwent mitral valve replacement with a mechanical prosthesis. Histopathological evaluation of the resected valve revealed leaflet thickening with a nodular appearance due to fibrous tissue containing atypical T-lymphocytes with Foxp3 expression, infiltrating all layers...
13
artículo
Publicado 2019
Enlace
Enlace
Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and safety of mogamulizumab in ATL patients with acute, lymphoma, and chronic subtypes with relapsed/refractory, aggressive disease in the US, Europe, and Latin America. With stratification by subtype, patients were randomized 2:1 to intravenous mogamulizumab 1.0 mg/kg once weekly for 4 weeks and biweekly thereafter (n=47) or investigator's choice of chemotherapy (n=24). The primary end point was confirmed overall response rate (cORR) confirmed on a subsequent assessment at 8 weeks by blinded independent review. ORR was 11% (95%CI: 4-23%) and 0% (95%CI: 0-14%) in the mogamulizumab and chemotherapy arms, respectively. Best response was 28% an...
14
artículo
Publicado 2014
Enlace
Enlace
Presenta la revisión de la literatura de todos los casos publicados de linfoma anaplásico de células grandes (ALCL por sus siglas en inglés) asociados a implantes mamarios desde 1997 hasta diciembre de 2012 y se estableció contacto con los autores correspondientes para actualizar el seguimiento clínico del ALCL.
